

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Botanix Pharmaceuticals Ltd

ABN

70 009 109 755

Quarter ended ("current quarter")

30 June 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for		
(a) staff costs	-	-
(b) advertising and marketing	-	-
(c) research and development	(29)	(29)
(d) leased assets	-	-
(e) other working capital	(84)	(358)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	2	11
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other (provide details if material)	-	-
(a) Takor transaction	-	(114)
(b) Botanix transaction	(92)	(101)
(c) R&D tax refund	88	88
Net operating cash flows	(115)	(503)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (12 months) \$A'000
1.8 Net operating cash flows (carried forward)	(115)	(503)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	(100)
(a) Loan to Takor Group Pty Ltd	-	(300)
(b) Convertible Note in Takor Group Pty Ltd		
1.12 Loans repaid by other entities		
1.13 Other (provide details if material)		
- cash acquired from business acquisition (Botanix Pharmaceuticals Inc)	- 33	- 33
Net investing cash flows	33	(367)
1.14 Total operating and investing cash flows	(82)	(870)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	3,434 ⁽¹⁾	3,434
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other – Capital Raising Costs	(193)	(193)
Net financing cash flows	3,241	3,241
Net increase (decrease) in cash held	3,159	2,371
1.21 Cash at beginning of quarter/year to date	521	1,309
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	3,680	3,680

⁽¹⁾ A further \$66,000 was received in the first week of July 2016 for total capital raised of \$3,500,000 pursuant to the Prospectus dated 13 May 2016 and the Supplementary Prospectus dated 24 June 2016.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	81
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	<p>Explanation necessary for an understanding of the transactions</p> <p>Payments to related parties reported include payments arising from operating activities for salaries and fees to Directors and their associates, payments to a company associated with Mr Hannaford relating to company secretarial services, accounting and bookkeeping services, and the provision of office accommodation, as well as payments to a company associated with Mr Towner relating to provision of advisory services to the Company.</p>	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Not Applicable

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Not Applicable

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	-	-
3.2 Credit standby arrangements	-	-

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	3,680	521
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	3,680	521

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Botanix Pharmaceuticals Inc	Not Applicable
5.2 Place of incorporation or registration	Delaware, USA	-
5.3 Consideration for acquisition or disposal	Total consideration of \$3,310,995.15, comprised of:- - Share consideration of \$3,129,328 being 156,476,642 shares at a deemed issue price of 2 cents each (including 3,476,642 shares issued as partial repayment of vendor working capital loans); and - Cash payment of \$181,667.15 as repayment of vendor working capital loans	-
5.4 Total net liabilities	(148,283)	-
5.5 Nature of business	Pharmaceutical development	-

+ See chapter 19 for defined terms.

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Company Secretary

Print name: Mr Brett Tucker

Date: 26 July 2016

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.